United States Hypophosphatasia Molecular Research Center

Status Recruiting

Clinical Trial Summary

This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.

Clinical Trial Description

Primary Study Objectives: Determine if cryptic alterations exist within or near to the ALPL gene in patients with clinical diagnosis of hypophosphatasia, but without identifiable pathogenic or likely pathogenic variant on commercial testing. Secondary Study Objective(s): Characterize functional effects of variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia Further characterize the differential diagnosis of hypophosphatasemia in patients with skeletal disease ;

Study Design

Related Conditions & MeSH terms

Hypophosphatasia

Clinical Trial Details

NCT number	NCT05062629
Study type	Observational
Source	Children's Mercy Hospital Kansas City
Contact	Eric Rush
Phone	816-302-3290
Email	hpp@cmh.edu
Status	Recruiting
Phase
Start date	August 24, 2021
Completion date	August 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03418389` - Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
Recruiting	`NCT02237625` - Natural History Study of Patients With Hypophosphatasia (HPP)
Completed	`NCT02291497` - Burden of Disease in Hypophosphatasia (HPP)	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Active, not recruiting	`NCT04195763` - Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
Not yet recruiting	`NCT05596539` - Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
Completed	`NCT02796885` - Characterisation of Adult-Onset Hypophosphatasia
Completed	`NCT02751801` - Health Burden of Hypophosphatasia
Completed	`NCT05890794` - Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia	Phase 1/Phase 2
Recruiting	`NCT06079359` - Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP	Phase 3
Recruiting	`NCT05234567` - A Prospective Sub-Study of the Global Hypophosphatasia Registry
Completed	`NCT02797821` - Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)	Phase 2
Completed	`NCT01163149` - Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)	Phase 2
Completed	`NCT04925804` - Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
Completed	`NCT02531867` - Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan	Phase 4
Completed	`NCT01406977` - Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)	Phase 2
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT01176266` - Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)	Phase 2/Phase 3
Withdrawn	`NCT00894075` - Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)	Phase 2
Active, not recruiting	`NCT04222452` - The PORTRAIT Study